MWMichael Scott Wolfe

Michael Scott Wolfe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Scott Wolfe has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AHA1 Regulates Aβ Production via Modulation of APP Abundance and γ‐Secretase Assembly

    by Arshad Ali Noorani, Sadequl Islam, Emma Filip, Kevin Catalfano, Shravan Paswan, Vaishnavi Nagarajan, Heather M. Wilkins, Brian S. J. Blagg, Kun Zou, Michael S. Wolfe

    Deposition of amyloid β‐protein (Aβ) is a hallmark of Alzheimer's disease (AD), produced by γ‐secretase–mediated cleavage of amyloid precursor protein (APP). The 90‐kDa heat shock protein (Hsp90) co‐chaperone, activator of Hsp90 ATPase homolog 1 (AHA1), is known to promote the accumulation of toxic tau species; however, its effects on Aβ production remain unclear. Using cellular models—including human embryonic kidney 293 T (HEK293T) cells, stable HEK‐APP cells, presenilin 1/2 double‐knockout mouse embryonic fibroblasts (PS‐DKO MEFs), and Chinese hamster ovary (CHO) cells—in which AHA1 was experimentally manipulated, together with observational analyses of human iPSC‐derived neurons carrying an FAD‐linked APP mutation, we demonstrate that AHA1 regulates Aβ generation through two mechanisms: regulation of APP protein abundance through pathways that are at least partially independent of Hsp90 interaction and Hsp90‐dependent promotion of γ‐secretase assembly. Knockdown of endogenous AHA1 reduces Aβ production and decreases APP and γ‐secretase component levels, whereas AHA1 overexpression elevates Aβ generation and increases the expression of these proteins. The AHA1‐E67K mutant, which has impaired Hsp90 binding, lowers Aβ production and the levels of APP and γ‐secretase components compared with wild‐type AHA1. AHA1 associates with APP and APH1, an immature γ‐secretase component, indicating its role in APP proteolysis and Aβ production. Disruption of the AHA1/Hsp90 complex—through AHA1 knockdown, the E67K mutant, or a small‐molecule inhibitor—reduces γ‐secretase assembly. Notably, Familial AD mutations (APP‐C99‐I45F, PS1‐L286V) upregulate AHA1/Hsp90, elevating APP/APH1 and Aβ42 production. AHA1 knockdown rescues FAD‐linked Aβ42 overproduction in a mutant cell model, while AHA1 overexpression exacerbates PS1 mutant Aβ production. Collectively, these findings reveal that AHA1 regulates Aβ production by modulating APP abundance and γ‐secretase assembly, establishing AHA1 as a potential target for therapeutic intervention in AD. image

  • Open Access

    The γ-secretase complex: from discovery to a therapeutic target

    by Shweta R. Malvankar, Michael S. Wolfe

    γ-Secretase is an intricate intramembrane aspartyl protease that cleaves within the transmembrane domain of ∼150 substrates, plays critical roles in biology and disease, and is considered the ‘proteasome of the membrane’.


  • Open Access

    A C. elegans model of familial Alzheimer's disease shows age-dependent synaptic degeneration independent of amyloid β-peptide

    by Vaishnavi Nagarajan, Caitlin L. Libowitz, Brian D. Ackley, Michael S. Wolfe


  • Open Access

    A C. elegans model of familial Alzheimer’s disease shows age-dependent synaptic degeneration independent of amyloid β-peptide

    by Vaishnavi Nagarajan, Caitlin L. Libowitz, Brian D. Ackley, Michael S. Wolfe

    The membrane-embedded γ-secretase complex is involved in the intramembrane cleavage of ∼ 150 substrates. Cleavage of amyloid precursor protein (APP)-derived substrate C99 generates 38-43-residue secreted amyloid β-peptides (Aβ), with the aggregation-prone 42-residue form (Aβ42) particularly implicated in the pathogenesis of Alzheimer’s Disease (AD). However, whether Aβ42 is the primary driver of neurodegeneration in AD remains unclear. Dominant mutations in APP or presenilin—the catalytic component of γ-secretase—cause early-onset familial AD (FAD) and reduce one or more steps in the multi-step processive proteolysis of C99 to Aβ peptides, apparently through stabilization of γ-secretase enzyme-substrate (E-S) complexes. To investigate mechanisms of neurodegeneration in FAD, we developed new C. elegans models co-expressing wild-type or FAD-mutant C99 substrate and presenilin-1 (PSEN1) variants in neurons, allowing intramembrane processing of C99 to Aβ in vivo. We demonstrate that while FAD-mutation of either C99 or PSEN1 leads to age-dependent synaptic loss, proteolytically inactive PSEN1 did not. Designed mutations that allow stable E-S complex formation without Aβ42 or Aβ production likewise result in synaptic degeneration. Moreover, replacement of C99 with variants of a Notch1-based substrate revealed that disrupted processing of another γ-secretase substrate can similarly lead to synaptic degeneration. These results support a model in which synaptic loss can be triggered by toxic, stalled γ-secretase E-S complexes in the absence of Aβ production and not by simple loss of proteolytic function. This new C. elegans system provides a powerful platform to study the role of dysfunctional γ-secretase substrate processing in FAD pathogenesis. SIGNIFICANCE: Dominantly inherited familial Alzheimer’s disease (FAD) is caused by mutations in the enzyme or substrate that produces amyloid β-peptides (Aβ). These mutations alter enzyme processing of substrate to Aβ and can skew production of Aβ to aggregation-prone forms that deposit as pathological plaques. Nevertheless, whether Aβ is the primary driver of AD remains unresolved. Recent evidence supports a model in which loss of neuronal connections in FAD is due to the stalled enzymatic process of Aβ production, rather than the Aβ products. Using the roundworm C. elegans as a genetic model system, we show here that the stalled process itself, rather than Aβ or reduced enzyme activity, can trigger loss of neuronal connections with age in this simple model animal.


  • γ-Secretase-Mediated Endoproteolysis of Neuregulin-1 and E-Cadherin

    by Shweta R. Malvankar, Michael S. Wolfe

    γ-Secretase is an intramembrane protease complex with nearly 150 substrates that are cleaved within their transmembrane domains (TMD). Amyloid Precursor Protein (APP) is the most widely studied, as processive proteolysis by γ-secretase releases the amyloid-β-peptide (Aβ) implicated in the pathogenesis of Alzheimer's disease. In contrast, the proteolysis of other substrates has been little explored. The only known sequence specificity rule for γ-secretase cleavage is for APP, in which phenylalanine is not tolerated at P2' with respect to any step in processive proteolysis. Recently, we found that this specificity rule applies to the initial cleavage of Notch1 substrate as well. In this study, we examined the site of initial cleavage by γ-secretase and explored the phenylalanine rule for two other γ-secretase substrates: neuregulin1 (NRG1) and E-cadherin (CDH1). Upon incubation of recombinant substrates with purified protease complex, followed by mass spectroscopy (MS) and immunoblot analysis, the initial cleavage products for NRG1 and CDH1 were identified. Two cleavage sites were observed in the NRG1 TMD, one of which matched that seen previously. However, the observed single CDH1 TMD cleavage site differed from that of the reported cytosolic cleavage site. Phenylalanine mutants of NRG1 and CDH1 in the P2' position relative to the first γ-secretase cleavage site showed a shift in the cleavage site, along with a reduction in total C-terminal and N-terminal products, compared to that seen with wild-type substrates. Taken together, these findings clarify the initial cleavage sites of NRG1 and CDH1 and support the intolerance of Phe at the P2' position as a general rule for γ-secretase substrates.


  • Open Access

    Presenilin-1 Familial Alzheimer Mutations Impair γ-Secretase Cleavage of APP Through Stabilized Enzyme–Substrate Complex Formation

    by Sujan Devkota, Masato Maesako, Michael S. Wolfe

    Familial Alzheimer’s disease (FAD) is caused by dominant missense mutations in amyloid precursor protein (APP) and presenilin-1 (PSEN1), the catalytic component of γ-secretase that generates amyloid β-peptides (Aβ) from the APP C-terminal fragment C99. While most FAD mutations increase the ratio of aggregation-prone Aβ42 relative to Aβ40, consistent with the amyloid hypothesis of Alzheimer pathogenesis, some mutations do not increase this ratio. The γ-secretase complex produces amyloid β-peptide (Aβ) through processive cleavage along two pathways: C99 → Aβ49 → Aβ46 → Aβ43 → Aβ40 and C99 → Aβ48 → Aβ45 → Aβ42 → Aβ38. Understanding how FAD mutations affect the multistep γ-secretase cleavage process is critical for elucidating disease pathogenesis. In a recent study, we discovered that FAD mutations lead to stalled γ-secretase/substrate complexes that trigger synaptic loss independently of Aβ production. Here, we further investigate this “stalled complex” hypothesis, focusing on five additional PSEN1 FAD mutations (M84V, C92S, Y115H, T116I, and M139V). A comprehensive biochemical analysis revealed that all five mutations led to substantially reduced initial proteolysis of C99 to Aβ49 or Aβ48 as well as deficiencies in one or more subsequent trimming steps. Results from fluorescence lifetime imaging microscopy support increased stabilization of enzyme–substrate complexes by all five FAD mutations. These findings provide further support for the stalled complex hypothesis, highlighting that FAD mutations impair γ-secretase function by promoting the accumulation of stalled enzyme–substrate complexes.


  • Open Access

    Familial Alzheimer Mutations in Presenilin-1 Decrease APP Substrate Proteolysis by γ-Secretase via Stable Enzyme-Substrate Complex Formation

    by Sujan Devkota, Masato Maesako, Michael S. Wolfe

    Familial Alzheimer’s disease (FAD) is caused by dominant missense mutations in am-yloid precursor protein (APP) and presenilin-1 (PSEN1), the catalytic component of γ-secretase, that generates amyloid β-peptides (Aβ) from the APP C-terminal fragment C99. While most FAD mutations increase the ratio of aggregation-prone Aβ42 relative to Aβ40, consistent with the amyloid hypothesis of Alzheimer pathogenesis, some muta-tions do not increase this ratio. The γ-secretase complex produces amyloid β-protein (Aβ) through processive cleavage along two pathways: C99→Aβ49→Aβ46→Aβ43→Aβ40 and C99→Aβ48→Aβ45→Aβ42→Aβ38. Under-standing how FAD mutations affect the multistep γ-secretase cleavage process is critical for elucidating disease pathogenesis. In a recent study, we discovered that FAD mutations lead to stalled γ-secretase/substrate complexes that trigger synaptic loss inde-pendently of Aβ production. Here, we further investigate this "stalled complex" hypothesis, focusing on five additional PSEN1 FAD mutations under study by the Dominantly Inherited Alzheimer Network (DIAN). Comprehensive biochemical analysis revealed that all five mutations led to substantially reduced initial proteolysis of C99 to Aβ49 or Aβ48 as well as deficiencies in one or more trimming steps. Results from fluorescence lifetime imaging microscopy support increased stabilization of enzyme-substrate complexes by all five FAD mutations. These findings provide further support for the stalled complex hypothesis, highlighting that FAD mutations impair γ-secretase function by promoting the accumulation of stalled enzyme-substrate complexes.

  • Open Access

    γ-Secretase-mediated endoproteolysis of neuregulin-1 and E-cadherin

    by Shweta R. Malvankar, Michael S. Wolfe

    γ-Secretase is an intramembrane protease complex, with nearly 150 substrates that are cleaved within their transmembrane domains (TMD). Amyloid Precursor Protein (APP) is the most widely studied, as processive proteolysis by γ-secretase releases the amyloid-β-peptide (Aβ) implicated in the pathogenesis of Alzheimer’s disease. In contrast, proteolysis of other substrates has been little explored. The only known sequence specificity rule for γ-secretase cleavage is for APP, in which phenylalanine is not tolerated at P2’ with respect to any step in processive proteolysis. Recently, we found this specificity rule applies to the initial cleavage of Notch1 substrate as well. In this study, we examined the site of initial cleavage by γ-secretase and explored the phenylalanine rule for two other γ-secretase substrates: neuregulin1 (NRG1) and E-cadherin (CDH1). Upon incubation of recombinant substrates with purified protease complex, followed by mass spectroscopy (MS) and immunoblot analysis, initial cleavage products for NRG1 and CDH1 were identified. Two cleavage sites were observed in the NRG1 TMD, one of which matched that seen previously. However, the observed single CDH1 TMD cleavage site differed from the reported cytosolic cleavage site. Phenylalanine mutants of NRG1 and CDH1 in the P2’ position relative to the first γ-secretase cleavage site showed a shift in the cleavage site, along with reduction in total C-terminal and N-terminal products, compared to that seen with wild-type substrates. Taking together, these findings clarify the initial cleavage sites of NRG1 and CDH1 and support the intolerance of Phe at P2’ position as a general rule for γ-secretase substrates. For Table of Contents use only:

  • Presenilin, γ-Secretase, and the Search for Pathogenic Triggers of Alzheimer’s Disease

    by Michael S. Wolfe

    Cerebral plaques of the amyloid β-peptide (Aβ) are a defining pathology in Alzheimer's disease (AD). The amyloid hypothesis of AD pathogenesis has dominated the field for over 30 years, ostensibly validated by rare AD-causing mutations in the substrate and enzyme that produce Aβ. The γ-secretase complex carries out intramembrane proteolysis of the substrate derived from the amyloid precursor protein (APP). Mutations in APP and presenilin, the catalytic component of γ-secretase, typically increase the ratio of aggregation-prone 42-residue Aβ (Aβ42) over the more soluble 40-residue form (Aβ40). Nevertheless, the inability to clarify how Aβ aggregation leads to neurodegeneration, along with poor progress in developing effective AD therapeutics that target Aβ, raises concern about whether Aβ is the primary disease driver. γ-Secretase carries out processive proteolysis on the APP substrate, producing long Aβ peptides that are generally trimmed in tripeptide intervals to shorter secreted peptides. Recent studies on effects of AD-causing mutations on the complicated proteolytic processing of the APP substrate by γ-secretase has led to the discovery that these mutations reduce─but do not abolish─processive proteolysis. Reduced proteolysis is apparently due to stabilization of enzyme-substrate complexes, and these stalled substrate-bound γ-secretase complexes can trigger synaptic degeneration even in the absence of Aβ production. Thus, the stalled process rather than the proteolytic products may be a principal initiator of AD pathogenesis. This new amyloid-independent hypothesis suggests that pharmacological agents that rescue stalled γ-secretase enzyme-substrate complexes might be effective therapeutics for AD prevention and/or treatment.


  • Effects of Transmembrane Phenylalanine Residues on γ-Secretase-Mediated Notch-1 Proteolysis

    by Shweta R. Malvankar, Michael S. Wolfe

    γ-Secretase is a presenilin-containing intramembrane aspartyl protease complex that cleaves within the transmembrane domain (TMD) of nearly 150 substrates, with the amyloid precursor protein (APP) being the most well studied. APP cleavage by γ-secretase generates amyloid β-peptides (Aβ) that pathologically deposit in Alzheimer's disease. The APP TMD substrate undergoes initial endoproteolysis (ε-cleavage) followed by processive carboxypeptidase trimming of long Aβ intermediates in ∼tripeptide intervals. Although γ-secretase cleavage of Notch1 is essential in developmental biology and is altered in many cancers, the processing of this cell-surface receptor is relatively understudied. Only one sequence specificity rule is known for γ-secretase substrate processing: Aromatic residues such as phenylalanine are not tolerated in the P2' position with respect to any processing event on the APP TMD. Here we show using biochemical and mass spectrometry (MS) techniques that this specificity rule holds for Notch1 as well. Analysis of products from the reactions of a purified enzyme complex and Notch1 TMD substrate variants revealed that P2' Phe relative to ε-site cleavage reduced proteolysis and shifted initial cleavage N-terminally by one residue. Double Phe mutation near the ε site resulted in reduced proteolysis with shifting to two major initial cleavage sites, one N-terminally and one C-terminally, both of which avoid Phe in the P2' position. Additionally, three natural Phe residues were mutated to the corresponding residues in the APP TMD, which led to increased ε proteolysis. Thus, Phe residues can affect the enzyme reaction rate as well as cleavage site specificity in the Notch1 TMD.